Kothawala Prajesh, Badamgarav Enkhe, Ryu Seonyoung, Miller Ross M, Halbert R J
Cerner LifeSciences, 9100 Wilshire Blvd, Ste 655E, Beverly Hills, CA 90212, USA.
Mayo Clin Proc. 2007 Dec;82(12):1493-501. doi: 10.1016/S0025-6196(11)61093-8.
To quantify the adherence of patients to drug therapy for osteoporosis in real-world settings via a systematic review and meta-analysis of observational studies.
The PubMed and Cochrane databases were searched for English-language observational studies published from January 1, 1990, to February 15, 2006, that assessed patient adherence to drug therapy for osteoporosis using the following medical subject headings and keywords: drug therapy, medication adherence, medication persistence, medication possession ratio, patient compliance, and osteoporosis. Studies were stratified into 3 groups: persistence (how long a patient continues therapy), compliance (how correctly, in terms of dose and frequency, a patient takes the medication), and adherence (a combination of persistence and compliance). A random-effects model was used to pool results from the selected studies.
Twenty-four studies were included in the meta-analysis. The pooled database-derived persistence rate was 52% (95% confidence interval [CI], 44%-59%) for treatment lasting 1 to 6 months, 50% (95% CI, 37%-63%) for treatment lasting 7 to 12 months, 42% (95% CI, 20%-68%) for treatment lasting 13 to 24 months, returning to 52% (95% CI, 45%-58%) for treatment lasting more than 24 months. Pooled adherence rates decreased from 53% (95% CI, 52%-54%) for treatment lasting 1 to 6 months to 43% for treatment lasting 7 to 12 months (95% CI, 38%-49%) or 13 to 24 months (43%; 95% CI, 32%-54%). The pooled refill compliance estimate was 68% (95% CI, 63%-72%) for treatment lasting 7 to 12 months and 68% (95% CI, 67%-69%) for treatment lasting 13 to 24 months. The pooled self-reported compliance rate was 62% (95% CI, 48%-75%) for treatment lasting 1 to 6 months and 66% (95% CI, 45%-81%) for treatment lasting 7 to 12 months.
One-third to half of patients do not take their medication as directed. Nonadherence occurs shortly after treatment initiation. Terms and definitions need to be standardized to permit comparability of technologies designed to improve patient adherence. Prospective trials are needed to assess the relationship between adherence and patient outcomes.
通过对观察性研究进行系统评价和荟萃分析,量化现实环境中患者对骨质疏松症药物治疗的依从性。
检索PubMed和Cochrane数据库,查找1990年1月1日至2006年2月15日发表的英文观察性研究,这些研究使用以下医学主题词和关键词评估患者对骨质疏松症药物治疗的依从性:药物治疗、药物依从性、药物持续性、药物持有率、患者依从性和骨质疏松症。研究分为3组:持续性(患者持续治疗的时间)、依从性(患者在剂量和频率方面服药的正确程度)和依从性(持续性和依从性的综合)。采用随机效应模型汇总所选研究的结果。
荟萃分析纳入了24项研究。治疗持续1至6个月时,汇总的基于数据库的持续性率为52%(95%置信区间[CI],44%-59%);治疗持续7至12个月时,为50%(95%CI,37%-63%);治疗持续13至24个月时,为42%(95%CI,20%-68%);治疗持续超过24个月时,回升至52%(95%CI,45%-58%)。汇总的依从率从治疗持续1至6个月时的53%(95%CI,52%-54%)降至治疗持续7至12个月时的43%(95%CI,38%-49%)或13至24个月时的43%(95%CI,32%-54%)。治疗持续7至12个月时,汇总的续方依从性估计值为68%(95%CI,63%-72%);治疗持续13至24个月时,为68%(95%CI,67%-69%)。治疗持续1至6个月时,汇总的自我报告依从率为62%(95%CI,48%-75%);治疗持续7至12个月时,为66%(95%CI,45%-81%)。
三分之一至一半的患者未按医嘱服药。不依从在治疗开始后不久就会出现。需要对术语和定义进行标准化,以实现旨在提高患者依从性的技术的可比性。需要进行前瞻性试验来评估依从性与患者预后之间的关系。